Inactive Instrument

Christian Hansen

CHR

DK0060227585

Chr. Hansen Holding A/S Reaffirms Financial Guidance for the Fiscal Year 2019

January 16, 2019

Chr. Hansen Holding A/S reaffirmed financial guidance for the fiscal year 2019. The company expects organic revenue growth in the range of 9% to 11%. The overall outlook for 2018/19 is unchanged compared to the announcement of October 15, 2018.

Latest news about Christian Hansen

Novozymes, Chr. Hansen Complete Merger Settlement	02-02	MT
Chr. Hansen Holding A/S(CPSE:CHR) dropped from OMX Nordic All-Share Index	02-01	CI
Chr. Hansen Holding A/S(CPSE:CHR) dropped from FTSE All-World Index	02-01	CI
Chr. Hansen Holding A/S(CPSE:CHR) dropped from S&P EUROPE 350 - Materials	02-01	CI
Chr. Hansen Holding A/S(CPSE:CHR) dropped from S&P EUROPE 350	02-01	CI
Chr. Hansen Holding A/S(CPSE:CHR) dropped from S&P EUROPE 350 - Materials (Industry Group)	02-01	CI
Chr. Hansen Holding A/S(CPSE:CHR) dropped from S&P International 700	02-01	CI
Chr. Hansen Holding A/S(CPSE:CHR) dropped from S&P Global 1200	02-01	CI
Chr. Hansen Holding A/S(CPSE:CHR) dropped from S&P Global BMI Index	02-01	CI
Chr. Hansen Holding A/S(CPSE:CHR) dropped from OMX Copenhagen 20 Index	01-30	CI
Novozymes Completes Merger with Chr. Hansen After Securing Final Registration, Issuing B Shares	01-29	MT
Novozymes A/S (CPSE:NZYM B) completed the acquisition of Chr. Hansen Holding A/S.	01-28	CI
Novozymes, Chr. Hansen’s Proposed Merger Secures All Regulatory Approvals	01-26	MT
Nordic Stocks Decreased Wednesday; Kone B Posted Biggest Loss	01-17	DJ
Novozymes, Chr. Hansen Merger Wins Korean Regulatory Nod	12-20	MT
Novozymes-Chr. Hansen Merger Gets EU Nod After Proposed Asset Sale	12-12	MT
Kerry Group Buys Novozymes, Chr. Hansen Assets for EUR150 Million	12-12	DJ
European Commission clears Novozymes, Chr. Hansen merger	12-12	RE
Kerry Group plc agreed to acquire Lactase enzyme business from Chr. Hansen Holding A/S and Novozymes A/S (CPSE:NZYM B) for ?150 million.	12-11	CI
Simon Barnard: A long-term vision at Smithson	12-07
EU regulators likely to clear Novozymes, Chr. Hansen deal, sources say	12-06	RE
EU ANTITRUST REGULATORS LIKELY TO APPROVE NOVOZYMES, C…	12-06	RE
EU Competition Watchdog Extends Novozymes, Chr. Hansen Merger Decision	11-21	MT
EU extends decision date on Novoyzmes, Chr. Hansen deal to Dec. 12	11-21	RE
Novozymes, Chr. Hansen Propose Remedy to Secure EU Approval for Merger	11-20	MT

Chart Christian Hansen

Duration

Period

More charts

Company Profile

Chr. Hansen Holding A/S specializes in the development, production and marketing of biotechnological ingredients for the food processing, animal feed and health industries. Net sales (excluding activities being sold) break down by family of products as follows: - cultivations and enzymes (62.6%); - medical and nutritional ingredients (37.4%): used in the manufacturing of dietary supplements, OTC drugs, baby products and animal feed. Net sales are distributed geographically as follows: Denmark (0.8%), Europe/Middle East/Africa (36.4%), the United States (30.3%), North America (2.4%), Asia/Pacific (18.7%) and Latin America (11.4%).

Sector

Food Processing

Calendar

2024-08-14 - Q2 2024 Earnings Release

More about the company

Sector Food Ingredients

	1st Jan change	Capi.
FOSHAN HAITIAN FLAVOURING AND FOOD COMPANY LTD.	-7.51%	26.19B
INTERNATIONAL FLAVORS & FRAGRANCES INC.	+19.50%	25.05B
KIKKOMAN CORPORATION	+14.49%	11.54B
LANCASTER COLONY CORPORATION	+14.80%	5.21B
MEIHUA HOLDINGS GROUP CO.,LTD	+8.80%	4.14B
ANGEL YEAST CO., LTD	-17.06%	3.39B
KEWPIE CORPORATION	+55.24%	3.31B
TATE & LYLE PLC	-3.87%	3.16B
JONJEE HI-TECH INDUSTRIAL AND COMMERCIAL HOLDING CO.,LTD	-30.14%	2.01B

Food Ingredients